TR200000562T2 - Amlodifin ve bir statin bileşiği içeren bileşim terapisi - Google Patents

Amlodifin ve bir statin bileşiği içeren bileşim terapisi

Info

Publication number
TR200000562T2
TR200000562T2 TR2000/00562T TR200000562T TR200000562T2 TR 200000562 T2 TR200000562 T2 TR 200000562T2 TR 2000/00562 T TR2000/00562 T TR 2000/00562T TR 200000562 T TR200000562 T TR 200000562T TR 200000562 T2 TR200000562 T2 TR 200000562T2
Authority
TR
Turkey
Prior art keywords
statin compound
therapy containing
containing amlodipine
composition therapy
amlodipine
Prior art date
Application number
TR2000/00562T
Other languages
English (en)
Inventor
Buch Jan
Andrew Donald Scott Robert
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22011309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000562(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of TR200000562T2 publication Critical patent/TR200000562T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Bu bulus, amlodifin veya bunun farmakolojik olarak uygun asit ekleme tuzlari ve statinler veya bunlarin farmakolojik olarak uygun tuzlarindan olusan farmakolojik bilesimlerle, bu gibi bilesimleri içeren donanimlarla, anjin pektoris, aterosklerosis, hipertansiyon ve hiperlipidemia'nin birlikte bulundugu durumlardan rahatsizlik çeken öznelerin tedavisinde ve insanlar da dahil olmak üzere kalp hastaliklariyla ilgili risk tasiyan öznelerin tedavisinde bu gibi bilesimleri kullanma metodlariyla ilgilidir.
TR2000/00562T 1997-08-29 1998-08-10 Amlodifin ve bir statin bileşiği içeren bileşim terapisi TR200000562T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5755597P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
TR200000562T2 true TR200000562T2 (tr) 2000-08-21

Family

ID=22011309

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00562T TR200000562T2 (tr) 1997-08-29 1998-08-10 Amlodifin ve bir statin bileşiği içeren bileşim terapisi

Country Status (36)

Country Link
US (1) US20020025981A1 (tr)
EP (1) EP1003507A1 (tr)
JP (1) JP2001514224A (tr)
KR (1) KR20010022385A (tr)
CN (1) CN1117566C (tr)
AP (1) AP1207A (tr)
AR (1) AR017514A1 (tr)
AU (1) AU744982B2 (tr)
BG (1) BG104076A (tr)
BR (1) BR9811558A (tr)
CA (1) CA2296726C (tr)
CO (1) CO4970726A1 (tr)
DZ (1) DZ2600A1 (tr)
EA (1) EA002705B1 (tr)
GT (1) GT199800134A (tr)
HN (1) HN1998000124A (tr)
HR (1) HRP980475A2 (tr)
HU (1) HUP0003103A3 (tr)
ID (1) ID24275A (tr)
IL (2) IL133957A0 (tr)
IS (1) IS5345A (tr)
MA (1) MA26539A1 (tr)
NO (1) NO20000999D0 (tr)
NZ (1) NZ502283A (tr)
OA (1) OA11289A (tr)
PA (1) PA8457201A1 (tr)
PE (1) PE106999A1 (tr)
PL (1) PL339088A1 (tr)
SA (1) SA98190432A (tr)
SK (1) SK1392000A3 (tr)
TN (1) TNSN98158A1 (tr)
TR (1) TR200000562T2 (tr)
UY (1) UY25159A1 (tr)
WO (1) WO1999011263A1 (tr)
YU (1) YU2700A (tr)
ZA (1) ZA987843B (tr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333624T2 (de) 1992-05-19 2005-09-15 Novogen Research Pty. Ltd., North Ryde Verwendung von isoflavon phyto-östrogen extrakten von soja oder klee
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
WO2002017913A1 (en) * 2000-08-30 2002-03-07 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
BR0306643A (pt) 2002-01-17 2004-10-19 Pharmacia Corp Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005097191A2 (en) * 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100742432B1 (ko) * 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
CA2645281A1 (en) 2006-03-29 2007-10-04 Kowa Co., Ltd. Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023958A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
MX2007008440A (es) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Composicion farmaceutica combinada.
KR20090091085A (ko) * 2008-02-22 2009-08-26 한올제약주식회사 방출성이 제어된 약제학적 제제
WO2009125987A2 (ko) * 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
WO2010008203A2 (ko) * 2008-07-15 2010-01-21 한올제약주식회사 칼슘채널길항제를 포함하는 약제학적 제제
CN101804055B (zh) * 2010-04-27 2012-01-25 施慧达药业集团(吉林)有限公司 复方药物制剂
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
TW201628625A (zh) * 2015-02-06 2016-08-16 英特賽普醫藥品公司 組合療法醫藥組成物
ES3031007T3 (en) * 2017-11-10 2025-07-03 Op T Llc Peptide for preventing, modulating and/or reducing cardiovascular disease
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
CN114727955B (zh) * 2019-11-25 2024-03-26 福多兹制药公司 包含降脂和降血压药物的制剂
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN176897B (tr) * 1993-10-29 1996-09-28 Cadila Lab Ltd
DE19539363A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen

Also Published As

Publication number Publication date
HUP0003103A3 (en) 2002-03-28
DZ2600A1 (fr) 2003-03-01
EP1003507A1 (en) 2000-05-31
YU2700A (sh) 2002-06-19
IS5345A (is) 2000-01-14
US20020025981A1 (en) 2002-02-28
EA002705B1 (ru) 2002-08-29
HN1998000124A (es) 1999-02-09
WO1999011263A1 (en) 1999-03-11
ZA987843B (en) 2000-02-28
JP2001514224A (ja) 2001-09-11
ID24275A (id) 2000-07-13
UY25159A1 (es) 2000-12-29
AP1207A (en) 2003-09-20
HK1029530A1 (en) 2001-04-06
MA26539A1 (fr) 2004-12-20
NO20000999L (no) 2000-02-28
HUP0003103A2 (hu) 2001-01-29
GT199800134A (es) 2000-02-08
PA8457201A1 (es) 2000-05-24
IL133957A (en) 2006-06-11
PL339088A1 (en) 2000-12-04
CA2296726A1 (en) 1999-03-11
BG104076A (en) 2000-09-29
AP9801333A0 (en) 1998-09-30
CN1117566C (zh) 2003-08-13
KR20010022385A (ko) 2001-03-15
CA2296726C (en) 2004-06-29
AU8458598A (en) 1999-03-22
SA98190432A (ar) 2005-12-03
IL133957A0 (en) 2001-04-30
CN1268054A (zh) 2000-09-27
BR9811558A (pt) 2000-08-22
NO20000999D0 (no) 2000-02-28
NZ502283A (en) 2002-05-31
OA11289A (en) 2003-08-25
PE106999A1 (es) 1999-11-06
AR017514A1 (es) 2001-09-12
AU744982B2 (en) 2002-03-07
SK1392000A3 (en) 2000-08-14
TNSN98158A1 (fr) 2005-03-15
EA200000013A1 (ru) 2000-08-28
HRP980475A2 (en) 1999-06-30
CO4970726A1 (es) 2000-11-07

Similar Documents

Publication Publication Date Title
TR200000562T2 (tr) Amlodifin ve bir statin bileşiği içeren bileşim terapisi
IS5343A (is) Meðferðarlegar samsetningar sem innihalda amlódipín og atórvastatín
EA200300155A1 (ru) Терапевтическая комбинация ингибитора сетр и аторвастатина
TR200000563T2 (tr) Atorvastatin ve bir antihipertensif vasıta içeren bileşim terapisi.
BR9815039A (pt) Inibição da oxidação de lipoproteìna
TR200101470T2 (tr) Farmasötik bileşim terkipleri.
ATE288893T1 (de) Polymorphe form von atorvastatin-calcium
EE9600072A (et) Uudne ravimsegu, mis sisaldab ACE inhibiitorit ramipriili ja dihüdropüridiinühendit
EE9800080A (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
TR199801195T2 (tr) Tedavide yararli kinolin ve kinozilin bilesikleri.
BR9914044A (pt) ésteres tetrahidropirido
BG106128A (bg) Обща сол на aмлодипин и аторвастатин
ATE272398T1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
UY27402A1 (es) Composiciones farmacéuticas de amlodipina y atorvastatina
DE69614149D1 (de) Chinolinderivate als antimalariamittel
BG106149A (bg) Съвместни пролекарствени средства на амлодипин и аторвастатин
TR200000020T2 (tr) 5-HT3 ve 5-HT4 aracılı bozuklar için faydalı (+)-norsisaprit.
TR200001869T2 (tr) Terapetik Maddeler
BR9814945A (pt) Utilização de fanquinona para o tratamento de doença de alzheimer, composição farmacêutica e kit
DE69710305D1 (de) Derivate von 4-Vinyl-4'-alpha-hydroxyethyl-biphenyl
NO963482L (no) Medisinsk anvendelse av bromelain
ATE204167T1 (de) Antikonvulsive derivate zur behandlung von psoriasis
ATE203530T1 (de) Adamantyl substituierte oxindole als pharmazeutische wirkstoffe
ECSP982646A (es) Combinaciones terapeuticas